Good News! Diabetes Drug May Slow Alzheimer’s Progression
Alzheimer’s Disease (AD) is the most common type of dementia. Of the estimated 50 million people living with dementia worldwide, 60-70% of them have Alzheimer’s.
Although there isn’t a cure for AD yet, there is newfound hope. A new study reveals a possible connection between a specific diabetes drug that can slow Alzheimer’s progression.
Could this lead to a breakthrough in Alzheimer’s treatment? If so, it’ll improve the lives of millions!
Diabetes and Alzheimer’s are each a complex subject. The possible effects of diabetic medications on AD patients are even more complicated. Let’s look at the key findings and their important implications.
South Korean research, involving 282 people aged around 76, just wrapped up its 6-year study. All participants had early Alzheimer’s and were divided into three groups:
- Group 1 – 70 patients – had stage 2 diabetes and were currently taking dipeptidyl peptidase-4 inhibitors (aka DDP-4i)
- Group 2 – 71 patients – had diabetes but were treated with other common diabetes drugs
- Group 3 – Control Group – 141 patients – did not have diabetes
All participants had brain scans (PET) before the start of the study. They also took the Mini-Mental State Exam (MMSE), a common test for thinking and memory, twice within a one-year period before the study. These requirements were used to qualify participants with a similar Alzheimer’s base level.
- Group 1, those patients taking DDP-4i, showed fewer plaques and a lower rate of cognitive decline than Groups 2 and 3.
- Furthermore, Group 1 patients continued to decline at a slower rate during follow-up tests. Read the full research article here.
Since this study was limited, more randomized clinical trials on DDP-4i are needed to determine its effect on slowing Alzheimer’s progression.
Significance of Early Diagnosis
Medical science cannot find ways to treat a disease without knowing it exists. Thanks to scientific innovation – for the first time in history – Amprion offers breakthrough biomarker testing to help physicians distinguish Alzheimer’s from other dementias in early stages.
Why is early so important? Because drugs work more effectively in the early stages. By detecting the disease early, physicians, patients, and their care team are empowered to take preventive steps to slow or stop Alzheimer’s. Some of these beneficial action steps include a brain-healthy diet, exercise, and lifestyle changes.
Early detection leads to research innovation to find a cure for Alzheimer’s.